ACAP3

ACAP3 is an Arf6-specific GTPase-activating protein (ArfGAP) that controls membrane trafficking events critical for neuronal development and receptor homeostasis. Its catalytic GAP activity, which promotes GTP hydrolysis on Arf6, is required for neurite outgrowth in hippocampal neurons and for radial migration of cortical neurons during brain development, with cycling between active and inactive Arf6 states—rather than constitutive locking in either state—being essential (PMID:27330119, PMID:28919417). In lung adenocarcinoma, ACAP3 functions as a tumor suppressor by impairing EGFR recycling and directing EGFR to lysosomal degradation in a GAP-activity-dependent manner, thereby attenuating EGFR signaling; its expression is epigenetically silenced by Myc-driven DNA methylation and histone deacetylation, and separately by HDAC2 in papillary thyroid carcinoma (PMID:41520057, PMID:39098591).

1. 2010 Low

   An intronic minisatellite (UPS29) within the ACAP3 locus was shown to have cell-type-specific enhancer activity favoring neuronal lineages, providing the first hint that ACAP3 expression is subject to tissue-specific cis-regulatory control.

   Evidence Reporter (EGFP) assays in HeLa, F9 embryonal carcinoma, and rat astrocyte cell lines

   PMID:21105360

   Open questions at the time

   • Reporter assay only; no demonstration that UPS29 regulates endogenous ACAP3 transcription
   • No chromatin context or transcription factor binding data provided
   • Functional relevance of different UPS29 allele lengths not established
2. 2016 High

   Establishing the core enzymatic identity of ACAP3: it was demonstrated to be an Arf6-specific GAP whose catalytic activity is required for neurite outgrowth, resolving the question of which Arf family member ACAP3 acts on and linking its biochemical function to a developmental process.

   Evidence In vitro GAP assay, GTP-Arf6 pulldown, knockdown and rescue with wild-type vs. GAP-inactive mutant in primary mouse hippocampal neurons

   PMID:27330119

   Open questions at the time

   • Direct structural basis for Arf6 specificity over other Arfs not determined
   • Downstream effectors linking Arf6 cycling to neurite extension not identified
   • Limited to cultured hippocampal neurons; in vivo relevance not yet shown
3. 2017 High

   The requirement for ACAP3 GAP activity was extended to an in vivo developmental process—cortical neuron migration—demonstrating that ACAP3-mediated Arf6 inactivation is essential for proper neuronal positioning in the cerebral cortex.

   Evidence In utero electroporation knockdown and GAP-mutant rescue in developing mouse cortex with cortical layer migration analysis

   PMID:28919417

   Open questions at the time

   • Specific membrane trafficking step regulated by ACAP3/Arf6 during migration not identified
   • No conditional knockout to assess postnatal or adult neuronal functions
   • Whether ACAP3 loss causes neurodevelopmental disease in humans is unknown
4. 2024 Medium

   ACAP3 was placed downstream of HDAC2-mediated epigenetic silencing in thyroid cancer, revealing that its tumor-suppressive effects—inhibiting proliferation, migration, and EMT—operate through modulation of AKT and p53 signaling.

   Evidence Overexpression/rescue experiments with HDAC2 and ACAP3 in papillary thyroid carcinoma cell lines, Western blot for AKT/p53 pathway components

   PMID:39098591

   Open questions at the time

   • No direct evidence that HDAC2 acts on the ACAP3 promoter (e.g., ChIP)
   • Whether AKT/p53 effects are mediated through Arf6 GAP activity is untested
   • Single cancer type; generalizability of the HDAC2-ACAP3 axis is unclear
5. 2026 Medium

   The mechanism of ACAP3 tumor suppression was resolved at the receptor trafficking level: ACAP3 impairs EGFR recycling and promotes its lysosomal degradation in a GAP-activity-dependent manner, while Myc-driven epigenetic silencing (DNA methylation and deacetylation) explains ACAP3 loss in lung adenocarcinoma.

   Evidence RRBS methylation profiling, EGFR recycling/trafficking assays, GAP-mutant rescue, in vivo xenograft proliferation assays in LUAD models

   PMID:41520057

   Open questions at the time

   • Whether Arf6 directly controls the EGFR recycling endosome in this context needs reconstitution
   • Structural basis of ACAP3 interaction with EGFR-containing compartments is unknown
   • Therapeutic relevance of re-expressing ACAP3 (e.g., via HDAC or DNMT inhibition) not tested in vivo

• Key unresolved questions include the structural basis of ACAP3 Arf6 specificity, the identity of direct downstream effectors linking Arf6 cycling to neurite outgrowth and cell migration, whether ACAP3 loss-of-function causes human neurodevelopmental disorders, and whether the neuronal and cancer trafficking functions converge on a shared Arf6-dependent membrane compartment.
• No structural model of ACAP3 catalytic domain with Arf6
• No human genetic disease association established by direct evidence
• Whether neuronal and EGFR-trafficking functions share an identical Arf6-dependent mechanism is unknown